^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    rovadicitinib (TQ05105)

    i
    Other names: TQ05105, Q05105
    Associations

    News

    Trials
    Company:
    Sino Biopharm
    Drug class:
    JAK inhibitor, ROCK inhibitor, ROCK2 inhibitor
    Related drugs:
    Associations

    News

    Trials
    22d
    TQ05105 Tablet for Myelofibrosis Treatment in Ruxolitinib-Resistant or Intolerant Patients (clinicaltrials.gov)
    P1, N=9, Active, not recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P1 trial
    |
    Jakafi (ruxolitinib) • rovadicitinib (TQ05105)
    2ms
    A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P2 trial
    |
    rovadicitinib (TQ05105)
    3ms
    A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF) (clinicaltrials.gov)
    P1/2, N=93, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P1/2 trial
    |
    TQB3909 • rovadicitinib (TQ05105)
    5ms
    A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF) (clinicaltrials.gov)
    P1/2, N=78, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    rovadicitinib (TQ05105)
    6ms
    A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF) (clinicaltrials.gov)
    P1/2, N=78, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P1/2 trial
    |
    rovadicitinib (TQ05105)
    7ms
    First-in-Class JAK/Rock Inhibitor Rovadicitinib in Myeloproliferative Neoplasms: A Single Arm, Multicenter, Open-Label, Phase I/Ib Study (ASH 2023)
    Rovadicitinib was generally safe, well-tolerated and showed meaningful clinical activity in patients with MF, especially with palpable splenomegaly. Rovadicitinib may be a new treatment option for myelofibrosis patients. Furthermore, a randomized double-blind phase 2 study is ongoing, aiming to assess the efficacy and safety of rovadicitinib compared to hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis in China (NCT05020652).
    Clinical • P1 data
    |
    JAK2 (Janus kinase 2) • CALR (Calreticulin)
    |
    JAK2 V617F • JAK2 mutation • CALR mutation
    |
    hydroxyurea • rovadicitinib (TQ05105)
    over1year
    JAK/ROCK INHIBITOR TQ05105 FOR GLUCOCORTICOID-REFRACTORY OR -DEPENDENT CHRONIC GRAFT-VERSUS-HOST DISEASE：UPDATED RESULTS OF A PHASE 1B/2 STUDY (EBMT 2023)
    TQ05105 demonstrated a tolerable safety and significant efficacy profile. The two dosages showed similar efficacy and slightly fewer AEs in 10mg BID, which is the preferred dosage as RP2D. Targeting JAK/ROCK pathways with TQ05105 is a therapeutically promising novel strategy for glucocorticoid-refractory or -dependent cGVHD.
    P1/2 data
    |
    JAK2 (Janus kinase 2) • JAK1 (Janus Kinase 1)
    |
    rovadicitinib (TQ05105)